JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab
We find that the combined metrics can be used to assess JCV immunocompetence, which can distinguish patients with and without PML, and could be used to predict and monitor PML patients from diagnosis onward to facilitate timely intervention.
Authors
- Qi Wu (ORCID: https://orcid.org/0000-0002-2550-3769)
- Yang Mao‐Draayer (ORCID: https://orcid.org/0000-0001-6248-3480)
- Guangmei Mao (ORCID: https://orcid.org/0000-0001-7840-3035)
- Elizabeth Mills (ORCID: https://orcid.org/0000-0002-0388-9437)
- Qin Wang (ORCID: https://orcid.org/0000-0002-2744-6497)
Institutions
- Alzheimer's Drug Discovery Foundation (US)
- University of Michigan (US)
- Oklahoma Medical Research Foundation (US)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fneur.2025.1584083
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Institute of Neurological Disorders and Stroke